Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EPS (Weighted Average and Diluted) (2016 - 2025)

Altimmune (ALT) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.21 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 34.38% to -$0.21 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.07, a 31.85% increase, with the full-year FY2024 number at -$1.34, up 19.28% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.21 for Q3 2025 at Altimmune, up from -$0.27 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.21 in Q3 2025 to a low of -$0.81 in Q3 2021.
  • A 5-year average of -$0.41 and a median of -$0.39 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 229.41% in 2021, then skyrocketed 41.07% in 2024.
  • Altimmune's EPS (Weighted Average and Diluted) stood at -$0.56 in 2021, then rose by 21.43% to -$0.44 in 2022, then fell by 27.27% to -$0.56 in 2023, then soared by 41.07% to -$0.33 in 2024, then skyrocketed by 36.36% to -$0.21 in 2025.
  • Per Business Quant, the three most recent readings for ALT's EPS (Weighted Average and Diluted) are -$0.21 (Q3 2025), -$0.27 (Q2 2025), and -$0.26 (Q1 2025).